FibroGen (FGEN) Scheduled to Post Quarterly Earnings on Tuesday

FibroGen (NASDAQ:FGEN) will be issuing its quarterly earnings data after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.02). The company had revenue of $55.90 million for the quarter, compared to the consensus estimate of $41.00 million. On average, analysts expect FibroGen to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

FibroGen Stock Performance

FibroGen stock traded down $0.53 during trading on Wednesday, reaching $0.50. The company had a trading volume of 6,413,250 shares, compared to its average volume of 2,592,510. The firm’s 50-day simple moving average is $1.08 and its 200 day simple moving average is $1.45. FibroGen has a 1-year low of $0.33 and a 1-year high of $2.93. The firm has a market capitalization of $49.73 million, a PE ratio of -0.42 and a beta of 0.71.

Analysts Set New Price Targets

Separately, William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research report on Monday, June 3rd.

Insiders Place Their Bets

In related news, insider Deyaa Adib acquired 22,123 shares of FibroGen stock in a transaction dated Wednesday, June 12th. The shares were acquired at an average cost of $1.17 per share, for a total transaction of $25,883.91. Following the completion of the purchase, the insider now owns 82,123 shares in the company, valued at $96,083.91. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.98% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.